Lumito publishes Year-end Report for 2020
Financial overview 2020 Financial overview of the fourth quarter, 1 October – 31 December 2020. Net sales amounted to kSEK 0 (0). Result after taxes amounted to kSEK -5,200 (-2,545). Basic and diluted earnings per share amounted to SEK -0.06 (-0.04) Cash flow from operating activities amounted to kSEK -5,198 (-3,145). Financial overview of the […]
New CEO of Lumito AB
The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. The Board of Directors of Lumito AB has resolved to appoint Mattias Lundin CEO of the Company. He will take office on March 8, 2021. Mattias Lundin is currently the […]
Lumito initiates process to engage in dialogue with future partners
The awareness about Lumito's (https://lumito.se/en/home/) potential is on the rise among companies active in digital pathology, and Lumito has received approaches from leading companies in health technologies and diagnostics. The interest in the Company demonstrates that Lumito is in just the right phase. Diagnostics is currently a bottleneck of the system. More and more laboratories abandon […]
Two European patents approved for tissue diagnostics
"Another milestone is passed as Lumito's third patent family now is granted in Europe as the first region. The patent (WO2018224688A1), ”A method of anaIysing a sampIe for at Ieast one anaIyte”, specifically contains the area of application that Lumito's first product launch is targetingand protects the Company's in vitro diagnostics based on upconversion nanoparticles (UCNP). We hope that […]
Delivery from RISE – Lumito proceeds to make optimizations on its own account
On behalf of Lumito, RISE has developed protocols for development of reagents for tissue staining based on UCNPs (UpConverting NanoParticles). The stained tissue samples are scanned with Lumitos scanner to obtain high-contrast imaging without background information. RISE delivered the results of the development effort at the end of June. During spring, Lumito has established a laboratory […]
Quarterly report 1, 2020, Lumito AB (publ).
Financial overview of the first quarter, 1 January – 31 March 2020 Result after taxes amounted to kSEK -2,795 (-1,958). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -2,793 (-1,958). Cash and cash equivalents amounted to kSEK 17,675 (8,079) on the balance sheet date. […]
Lumito AB Quarterly Report (1 October to 31 December) 2019
Financial overview of the fourth quarter, 1 October – 31 December 2019 Result after taxes amounted to kSEK -2,545 (-2,148). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -3,145 (-2,148). Financial overview of the year as a whole, 1 January – 31 December […]
Status update regarding the completion of Lumito’s first product
The development of Lumito’s first product (instrument + staining reagent) in digital tissue diagnostics, for analyzing tissue sections stained with the company’s nano-based staining reagents, is entering its final stage prior to launch. The development of the actual instrument is proceeding according to plan, and the first instruments, which are intended for customer validation at […]
First exercise window for Lumito warrants closes
On 29 November, Lumito AB (publ) (“Lumito”) ended the first exercise period for the Series 2 TO2 subscription warrant. The exercise rate was 72.3 percent, at an exercise price of SEK 1.45 per share. In total, 11,179,281 new shares have been subscribed during the now concluded first exercise period. Lumito is thus provided approximately MSEK […]
Lumito AB is provided approximately MSEK 38.7 in cash through an over-subscribed rights issue and a decided over-allotment
Lumito AB (publ) announces today that the Company's new share issue amounting to approximately MSEK 35.7 has been subscribed to a total of 155 percent. The commitments from the guarantee consortium do therefore not have to be utilized. In addition, an over-allotment issue of MSEK 3.0 has been decided. An extraordinary general meeting of Lumito […]